Table 3 Disease background of our patients
From: C1-inhibitor/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor deficiency
Patient ID | Gender | Age at the first angioedema attack | Underlying disorders | Treatment of underlying disorders |
|---|---|---|---|---|
P1 | M | 60 | – | – |
P2 | F | 40 | Marginal zone lymphoma | – |
P3 | F | 83 | MGUS | – |
P4 | F | – | – | – |
P5 | F | – | Non-Hodgkin lymphoma | Rituximab, ASCT |
P6 | F | 56 | Marginal zone lymphoma | Rituximab |
P7 | F | 61 | Chronic lymphoid leukemia | Rituximab |
P8 | M | 49 | MGUS | – |
P9 | F | 65 | Basal cell adenoma | – |
P10 | M | 70 | MGUS | Rituximab |
P11 | F | 49 | MGUS | – |
P12 | M | 59 | Myeloma multiplex | Chemotherapy (VAD), ASCT, rituximab |
P13 | M | 46 | Marginal zone lymphoma | Rituximab |
P14 | F | 71 | Marginal zone lymphoma | Rituximab |
P15 | M | 60 | – | – |
P16 | M | 42 | MGUS | – |
P17 | M | 76 | MGUS | – |
P18 | F | 71 | Marginal zone lymphoma | Rituximab |
P19 | M | 43 | – | – |